肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

欧洲CHMP在11月会议上建议批准5种药物上市

2020-11-16 MedSci原创 MedSci原创

乳腺癌流感开角型青光眼
关注

在11月的会议上，欧洲药品管理局人用药品委员会（CHMP）建议批准五种药物上市。

在11月的会议上，欧洲药品管理局人用药品委员会（CHMP）建议批准五种药物上市。

CHMP建议将Phesgo（pertuzumab/trastuzumab）用于治疗早期和转移性HER2阳性乳腺癌患者。Phesgo是HER二聚化抑制剂Perjeta（pertuzumab）和HER2单抗Herceptin（trastuzumab）与透明质酸酶的固定剂量组合，通过皮下注射给药。

See the source image

图片来源：www.cancernetwork.com

CHMP建议将Roclanda (latanoprost/netarsudil)滴眼液用于降低原发性开角型青光眼或高眼压成年患者的眼内压升高（IOP）。

Aerie's Rocklatan shows successful interim 90-day topline data | Optometry Times

图片来源：www.optometrytimes.com

CHMP建议将Xofluza（baloxavir marboxil）用于治疗12岁及以上的单纯性流感。还建议将罗氏该口服抗病毒药批准用于预防12岁及以上人群的流感。

XOFLUZA™ (baloxavir marboxil) Mechanism of Action| HCP

图片来源：www.xofluza.com

CHMP建议将抗VEGF单抗Onbevzi （罗氏贝伐单抗的仿制药）用于治疗结直肠癌，乳腺癌，非小细胞肺癌，肾细胞癌，卵巢上皮癌，输卵管，原发性腹膜癌和子宫颈癌。

Part:BBa K1694003 - parts.igem.org

图片来源：http://parts.igem.org/Part:BBa_K1694003

CHMP建议将靶向CD123的细胞毒素Elzonris（tagraxofusp）用于治疗弹状浆细胞样树突状细胞瘤（BPDCN）。

ELZONRIS MOA illustration

图片来源：https://elzonris.com/about-elzonris

原始出处：

https://www.firstwordpharma.com/node/1774524?tsid=28&region_id=6

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=900374, encodeId=edc89003e45f, content=很棒 , beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Thu Nov 19 09:08:45 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302691, encodeId=58eb1302691ec, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Nov 18 07:17:56 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339366, encodeId=ec44133936694, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Wed Nov 18 07:17:56 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899738, encodeId=2457899e38ef, content=有用！, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0d45220203, createdName=1477a9cbm52暂无昵称, createdTime=Mon Nov 16 23:33:39 CST 2020, time=2020-11-16, status=1, ipAttribution=)]
    2020-11-19 飞翔的乌龟

    很棒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=900374, encodeId=edc89003e45f, content=很棒 , beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Thu Nov 19 09:08:45 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302691, encodeId=58eb1302691ec, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Nov 18 07:17:56 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339366, encodeId=ec44133936694, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Wed Nov 18 07:17:56 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899738, encodeId=2457899e38ef, content=有用！, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0d45220203, createdName=1477a9cbm52暂无昵称, createdTime=Mon Nov 16 23:33:39 CST 2020, time=2020-11-16, status=1, ipAttribution=)]
    2020-11-18 医生2394

    #CHMP#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=900374, encodeId=edc89003e45f, content=很棒 , beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Thu Nov 19 09:08:45 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302691, encodeId=58eb1302691ec, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Nov 18 07:17:56 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339366, encodeId=ec44133936694, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Wed Nov 18 07:17:56 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899738, encodeId=2457899e38ef, content=有用！, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0d45220203, createdName=1477a9cbm52暂无昵称, createdTime=Mon Nov 16 23:33:39 CST 2020, time=2020-11-16, status=1, ipAttribution=)]
    2020-11-18 ms9474365431325850

    #欧洲#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=900374, encodeId=edc89003e45f, content=很棒 , beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Thu Nov 19 09:08:45 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302691, encodeId=58eb1302691ec, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Nov 18 07:17:56 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339366, encodeId=ec44133936694, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Wed Nov 18 07:17:56 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899738, encodeId=2457899e38ef, content=有用！, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0d45220203, createdName=1477a9cbm52暂无昵称, createdTime=Mon Nov 16 23:33:39 CST 2020, time=2020-11-16, status=1, ipAttribution=)]
    2020-11-16 1477a9cbm52暂无昵称

    有用！

    0

相关资讯

Lancet oncol：临床试验15年随访结果：放疗对I-III期乳腺癌预后的影响

多项研究的10年结果显示，乳腺癌患者术后添加部分或全区域淋巴结放疗可提高无进展存活率、无远处转移存活率，减少乳腺癌相关死亡率。现对EORTC 22922/10925试验的15年分析结果进行汇报。

JCO：为什么乳腺癌的四种复发风险预测分析结果不一样？

Oncotype DX复发评分（RS）、芯片50（PAM50）复发风险（ROR）的Prosigna预测分析、EndoPredict (EP)和乳腺癌指数（BCI）常用于临床评估接受内分泌治疗的患者远处

吓怕了！隆胸会导致乳腺癌？胸竟然跑到腰上了？到底是怎么回事？

“医生，我的胸跑到了腰上！”

Int J Cancer：习惯晚上运动？新研究发现：早上锻炼或许更有助于人们抗癌

众所周知，运动有益健康。但长期以来困扰人们的问题是，究竟是早上运动还是晚上运动产生的效果更好。最近的一项研究指出，在预防前列腺癌和乳腺癌患者方面，早上运动或许是更为理想的选择。

复旦肿瘤医院与华米共同研究：可穿戴设备可促进乳腺癌康复

近日，复旦大学附属肿瘤医院与华米科技(NYSE：HMI)的共同研究成果：《可穿戴设备为基础的生活方式干预对I-III期乳腺癌术后患者身体成分影响》，在Frontiers in Oncology发表。该

Br J Cancer：IRS-1介导ER+乳腺癌中PR驱动的干细胞性和内分泌抗性

乳腺癌作为女性中最常见的恶性肿瘤，在大多数的患者中（约75％）均检测到雌激素受体（ER）和孕激素受体（PR）的表达。靶向ER的疗法是目前该疾病的一种主要治疗手段，然而耐药性的产生在患者中特别普遍。当前